Takanori Teshima

Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation

Jonathan U. Peled, Antonio L. C. Gomes, Sean M. Devlin et al. · New England Journal of Medicine · 2020 · 676 citations · Full text

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Stephen J. Schuster, Constantine S. Tam, Peter Borchmann et al. · The Lancet Oncology · 2021 · 528 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +8

Acute graft-versus-host disease does not require alloantigen expression on host epithelium

Takanori Teshima, Rainer Ordemann, Pavan Reddy et al. · Nature Medicine · 2002 · 517 citations

Host Response, Graft-versus-host Disease, Transplantation +14

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nathan Fowler, Michael Dickinson, Martin Dreyling et al. · Nature Medicine · 2021 · 492 citations · Full text

Lymphoid Neoplasia, Hematology, Immunology +6

TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells

Yoshikane Kikushige, Takahiro Shima, Shin‐ichiro Takayanagi et al. · Cell stem cell · 2010 · 475 citations · Full text

Hematological Malignancy, Cell Therapy, Medicine +10